Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.7947
+0.0807 (11.30%)
At close: Feb 10, 2026, 4:00 PM EST
0.8200
+0.0253 (3.18%)
After-hours: Feb 10, 2026, 7:51 PM EST
Immunic Employees
Immunic had 90 employees as of September 30, 2025. The number of employees increased by 5 or 5.88% compared to the same quarter last year.
Employees
90
Change
5
Growth
5.88%
Revenue / Employee
n/a
Profits / Employee
-$1,144,967
Market Cap
95.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 90 | 5 | 5.88% |
| Jun 30, 2025 | 90 | 5 | 5.88% |
| Mar 31, 2025 | 90 | 10 | 12.50% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Sep 30, 2024 | 85 | 5 | 6.25% |
| Jun 30, 2024 | 85 | 10 | 13.33% |
| Mar 31, 2024 | 80 | 7 | 9.59% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Sep 30, 2023 | 80 | 15 | 23.08% |
| Jun 30, 2023 | 75 | 15 | 25.00% |
| Mar 31, 2023 | 73 | 18 | 32.73% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Sep 30, 2022 | 65 | 13 | 25.00% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 55 | 15 | 37.50% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Sep 30, 2021 | 52 | 24 | 85.71% |
| Jun 30, 2021 | 45 | - | - |
| Mar 31, 2021 | 40 | 14 | 53.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pliant Therapeutics | 171 |
| Adicet Bio | 152 |
| MindWalk Holdings | 102 |
| XBiotech | 88 |
| PolyPid | 60 |
| iBio, Inc. | 20 |
| MAIA Biotechnology | 13 |
| Pelthos Therapeutics | 11 |
IMUX News
- 6 days ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 4 weeks ago - Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PRNewsWire
- 2 months ago - Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - PRNewsWire
- 3 months ago - Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic to Participate in Industry and Investor Conferences in November - PRNewsWire
- 4 months ago - Immunic to Participate in Scientific and Investor Conferences in October - PRNewsWire
- 4 months ago - Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PRNewsWire
- 5 months ago - Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PRNewsWire